MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.080
-0.030 (-2.70%)
Aug 5, 2026, 2:57 PM EDT - Market open
MaxCyte Revenue
MaxCyte had revenue of $9.65M in the quarter ending March 31, 2026, a decrease of -7.11%. This brings the company's revenue in the last twelve months to $32.29M, down -14.30% year-over-year. In the year 2025, MaxCyte had annual revenue of $33.03M, down -14.50%.
Revenue (ttm)
$32.29M
Revenue Growth
-14.30%
P/S Ratio
3.68
Revenue / Employee
$354,802
Employees
91
Market Cap
115.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33.03M | -5.60M | -14.50% |
| Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
| Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
| Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
| Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
| Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
| Dec 31, 2019 | 21.62M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Neuronetics | 151.64M |
| Quanterix | 144.98M |
| Outset Medical | 117.59M |
| Owlet | 107.06M |
| AVITA Medical | 72.35M |
| CVRx, Inc. | 59.07M |
| Rapid Micro Biosystems | 34.38M |
| Hyperfine | 15.33M |
MXCT News
- 15 days ago - MaxCyte enters technology license partnership with Genentech - TheFly
- 15 days ago - MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development - GlobeNewsWire
- 20 days ago - MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 - GlobeNewsWire
- 6 weeks ago - VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
- 3 months ago - MaxCyte reports Q1 EPS (4c), consensus (9c) - TheFly
- 3 months ago - MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M - TheFly
- 3 months ago - MaxCyte Earnings Call Transcript: Q1 2026 - Transcripts
- 3 months ago - MaxCyte Earnings release: Q1 2026 - Filings